JP2018521008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521008A5 JP2018521008A5 JP2017560938A JP2017560938A JP2018521008A5 JP 2018521008 A5 JP2018521008 A5 JP 2018521008A5 JP 2017560938 A JP2017560938 A JP 2017560938A JP 2017560938 A JP2017560938 A JP 2017560938A JP 2018521008 A5 JP2018521008 A5 JP 2018521008A5
- Authority
- JP
- Japan
- Prior art keywords
- medi
- administration
- antibody
- binding fragment
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167625P | 2015-05-28 | 2015-05-28 | |
| US62/167,625 | 2015-05-28 | ||
| PCT/EP2016/061987 WO2016189124A1 (en) | 2015-05-28 | 2016-05-27 | Therapeutic combinations and methods for treating neoplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521008A JP2018521008A (ja) | 2018-08-02 |
| JP2018521008A5 true JP2018521008A5 (https=) | 2019-06-27 |
Family
ID=56117679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560938A Ceased JP2018521008A (ja) | 2015-05-28 | 2016-05-27 | 腫瘍形成を処置するための治療用組成物および治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160347848A1 (https=) |
| EP (1) | EP3303393A1 (https=) |
| JP (1) | JP2018521008A (https=) |
| KR (1) | KR20180011165A (https=) |
| CN (1) | CN107743400A (https=) |
| AR (1) | AR104812A1 (https=) |
| AU (1) | AU2016269145C1 (https=) |
| CA (1) | CA2986966A1 (https=) |
| IL (1) | IL255780A (https=) |
| RU (1) | RU2017144185A (https=) |
| TW (1) | TW201705981A (https=) |
| WO (1) | WO2016189124A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ718821A (en) | 2013-09-11 | 2022-07-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| PT3142751T (pt) * | 2014-05-13 | 2019-10-25 | Medimmune Ltd | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. |
| WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| RU2753493C2 (ru) * | 2016-12-15 | 2021-08-17 | Эббви Байотерапьютикс Инк. | Анти-ох40 антитела и их применение |
| ES2977788T3 (es) | 2017-04-20 | 2024-08-30 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2020014583A1 (en) * | 2018-07-13 | 2020-01-16 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor |
| BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
| US12012453B2 (en) * | 2019-09-05 | 2024-06-18 | Astrazeneca Ab | Methods for treating late-stage small cell lung cancer by administering a human anti-PD-L1 antibody, an etoposide and a platinum-based therapeutic |
| WO2021098851A1 (en) * | 2019-11-20 | 2021-05-27 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| JP2023525140A (ja) * | 2020-05-13 | 2023-06-14 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｏｘ４０活性化特性を有する組換えタンパク質 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| US20260061066A1 (en) * | 2024-06-03 | 2026-03-05 | Uct Bioscience Co., Ltd. | Anti-grp78 antibody, immunoconjugate and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7158164B2 (en) | 2003-08-29 | 2007-01-02 | Fuji Photo Film Co., Ltd. | Thermal development method and apparatus |
| DK2650020T3 (en) | 2005-05-06 | 2017-01-16 | Providence Health & Services - Oregon | Trimeric OX40 immunoglobulin fusion protein and methods for applications. |
| WO2007056539A2 (en) | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| AU2012369202A1 (en) | 2012-02-06 | 2014-09-25 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| AU2012371610A1 (en) | 2012-03-02 | 2014-10-02 | Providence Health & Services - Oregon | Dual OX40 agonist/IL-2 cancer therapy methods |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| RU2016142476A (ru) * | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| RU2017134104A (ru) * | 2015-03-11 | 2019-04-03 | Провиденс Хелт Энд Сервисиз-Орегон | Композиции и способы повышения эффективности противораковой терапии |
-
2016
- 2016-05-09 US US15/149,927 patent/US20160347848A1/en not_active Abandoned
- 2016-05-25 TW TW105116316A patent/TW201705981A/zh unknown
- 2016-05-27 AU AU2016269145A patent/AU2016269145C1/en not_active Ceased
- 2016-05-27 JP JP2017560938A patent/JP2018521008A/ja not_active Ceased
- 2016-05-27 EP EP16728250.8A patent/EP3303393A1/en not_active Withdrawn
- 2016-05-27 KR KR1020177036356A patent/KR20180011165A/ko not_active Withdrawn
- 2016-05-27 CN CN201680029691.5A patent/CN107743400A/zh active Pending
- 2016-05-27 RU RU2017144185A patent/RU2017144185A/ru not_active Application Discontinuation
- 2016-05-27 WO PCT/EP2016/061987 patent/WO2016189124A1/en not_active Ceased
- 2016-05-27 AR ARP160101560A patent/AR104812A1/es unknown
- 2016-05-27 CA CA2986966A patent/CA2986966A1/en not_active Abandoned
-
2017
- 2017-11-20 IL IL255780A patent/IL255780A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521008A5 (https=) | ||
| Wen et al. | Chronic inflammation, cancer development and immunotherapy | |
| Makaremi et al. | Immune checkpoint inhibitors in colorectal cancer: challenges and future prospects | |
| Zhou et al. | Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity | |
| Rajaraman et al. | Measles virus-based treatments trigger a pro-inflammatory cascade and a distinctive immunopeptidome in glioblastoma | |
| JP2021058197A5 (https=) | ||
| JP2018512397A5 (https=) | ||
| Filimon et al. | Interleukin-8 in melanoma pathogenesis, prognosis and therapy—an integrated view into other neoplasms and chemokine networks | |
| RU2017144185A (ru) | Терапевтические комбинации и способы лечения новообразований | |
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| JP2019536430A5 (https=) | ||
| Tai et al. | Rationale of immunotherapy in hepatocellular carcinoma and its potential biomarkers | |
| Wang et al. | Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade | |
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| Janssen et al. | Combinatorial immunotherapies for metastatic colorectal cancer | |
| JP2011103891A5 (https=) | ||
| JP2023511255A (ja) | ＴＧＦ－β阻害剤及びその使用 | |
| CN103906536A (zh) | 恶病质治疗 | |
| EP4291902A2 (en) | Biomarkers for cancer treatment | |
| Tella et al. | Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date | |
| Heinrich et al. | Translational considerations to improve response and overcome therapy resistance in immunotherapy for hepatocellular carcinoma | |
| Kim et al. | Strategies to overcome hurdles in cancer immunotherapy | |
| Becht et al. | New opportunities in the systemic treatment of hepatocellular carcinoma—today and tomorrow | |
| Yuan et al. | Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy | |
| CN114042154B (zh) | 一种药物组合在制备抗肿瘤的联合治疗药物中的应用 |